Theravance Biopharma, Inc. (TBPH) Income Annual - Discounting Cash Flows
TBPH
Theravance Biopharma, Inc.
TBPH (NASDAQ)
Period Ending: LTM
(Last Twelve Months)
2024
12-31
2023
12-31
2022
12-31
2021
12-31
2020
12-31
2019
12-31
2018
12-31
2017
12-31
2016
12-31
2015
12-31
2014
12-31
2013
12-31
2012
12-31
2011
12-31
Report Filing 2025-11-12 2025-03-07 2024-03-01 2023-03-01 2022-02-28 2021-02-26 2020-02-27 2019-02-28 2018-02-28 2017-03-01 2016-03-11 2015-03-13 2013-12-31 2012-12-31 2011-12-31
Revenue 80.33 64.38 57.42 51.35 55.31 71.86 73.41 60.37 15.39 48.65 42.13 11.69 0.226 130.1 14.85
Cost of Revenue 30.05 0 40.62 63.39 193.7 0 0 0.715 6.03 2.89 4.66 4.06 120.6 114 3.84
Gross Profit 50.27 64.38 16.8 -12.05 -138.3 71.86 73.41 59.66 9.36 45.75 37.47 7.63 -120.4 16.15 11.01
Operating Expenses 83.09 111.3 72.84 79.91 119.4 369.5 325.3 298.4 269.5 226.2 219.4 240.2 35.93 25.73 120.3
Research & Development 39.51 37.64 46.34 70.07 201.5 261 219.2 201.3 173.9 141.7 129.2 168.5 120.6 114 98.85
Selling, General and Administrative 18.5 69.17 70.45 67.07 0 108.5 106.1 97.06 95.59 84.51 90.2 71.65 35.93 25.73 21.5
Other Operating Expenses 25.08 4.51 -43.96 -57.24 -82.11 0 0 0 0 0 0 0 -120.6 -114 0
Operating Income -32.81 -46.95 -56.03 -91.96 -257.8 -297.6 -251.9 -238.8 -260.1 -180.5 -181.9 -232.5 -156.3 -9.57 -109.3
Net Non-Operating Interest 0.778 2.33 6.77 2.18 -7.44 -4.11 -23.47 1.48 -3.76 -0.092 0.631 1.86 0 0 0
Interest Income 3.3 4.88 9.12 8.54 1.11 4.44 8.39 11.97 4.79 1.31 0.631 1.86 0 0 0
Interest Expense 2.52 2.55 2.35 6.37 8.55 8.55 31.86 10.48 8.55 1.4 0 0 0 0 0
Equity & Other Income/(Expense) 79.28 0 0 -3.03 0 -1.61 33.7 11.18 -7.83 0 0 0 0 0 0
Income Before Tax 47.24 -44.61 -49.27 -92.81 -265.2 -303.3 -241.7 -226.1 -271.7 -180.6 -181.3 -230.7 -156.3 -9.57 -109.3
Income Tax Expense 17.9 11.8 5.92 0.009 -0.151 -8.52 -5.22 -10.56 13.69 10.11 0.951 6.36 0 0 0
Income Attributable to Non-Controlling Interest 0 0 0 -965 -65.64 -16.81 0 0 0 0 0 0 0 0 0
Net Income 29.34 -56.42 -55.19 872.1 -199.4 -278 -236.5 -215.5 -285.4 -190.7 -182.2 -237 -156.3 -9.57 -109.3
Depreciation and Amortization 1.93 3.62 2 3.04 4.81 6.97 6.21 3.17 4.03 3.12 2.99 2.66 2.65 3.25 3.84
EBITDA -30.89 -43.33 -54.03 -88.92 -253 -290.7 -245.7 -235.6 -256.1 -177.3 -178.9 -229.9 -153.6 -6.32 -105.5
Earnings Per Share (EPS) 0.58 -1.15 -1 -1.26 -2.87 -4.46 -4.25 -3.99 -5.45 -4.26 -5.34 -7.46 -4.92 -0.3 -3.43
Diluted Earnings Per Share 0.57 -1.15 -1 -1.26 -2.87 -4.46 -4.25 -3.99 -5.45 -4.26 -5.34 -7.46 -4.84 -0.3 -3.43
Weighted Average Shares Outstanding 50.52 48.85 55.3 73.59 69.46 62.34 55.61 53.97 52.35 44.71 34.15 31.75 31.74 31.74 31.9
Diluted Weighted Average Shares Outstanding 51.91 48.85 55.3 73.59 69.46 62.34 55.61 53.97 52.35 44.71 34.15 31.75 32.26 32.26 31.9
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program